Sound Shore Management Inc. CT Has $109.87 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Sound Shore Management Inc. CT reduced its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 9.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,761,446 shares of the company’s stock after selling 733,244 shares during the period. Teva Pharmaceutical Industries makes up about 3.7% of Sound Shore Management Inc. CT’s investment portfolio, making the stock its largest position. Sound Shore Management Inc. CT owned about 0.60% of Teva Pharmaceutical Industries worth $109,873,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. AE Wealth Management LLC increased its holdings in shares of Teva Pharmaceutical Industries by 29.0% during the 2nd quarter. AE Wealth Management LLC now owns 198,808 shares of the company’s stock worth $3,231,000 after purchasing an additional 44,718 shares during the period. Mark Sheptoff Financial Planning LLC bought a new position in Teva Pharmaceutical Industries during the second quarter valued at about $57,000. Seven Eight Capital LP acquired a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $1,384,000. Vanguard Personalized Indexing Management LLC lifted its position in shares of Teva Pharmaceutical Industries by 26.7% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 27,643 shares of the company’s stock worth $449,000 after acquiring an additional 5,831 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in shares of Teva Pharmaceutical Industries by 13.4% during the 2nd quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock worth $141,839,000 after purchasing an additional 1,031,400 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the transaction, the insider now owns 45,060 shares of the company’s stock, valued at approximately $777,285. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Stock Down 1.4 %

Shares of TEVA opened at $17.51 on Friday. The firm has a market capitalization of $19.83 billion, a price-to-earnings ratio of -42.70, a PEG ratio of 1.26 and a beta of 0.88. Teva Pharmaceutical Industries Limited has a 52 week low of $8.06 and a 52 week high of $19.08. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. The business’s fifty day moving average price is $17.66 and its two-hundred day moving average price is $16.07.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.03. The company had revenue of $4.16 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. On average, analysts predict that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current year.

Analysts Set New Price Targets

TEVA has been the topic of several analyst reports. Jefferies Financial Group boosted their price target on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Wednesday, July 10th. Barclays raised their target price on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 3rd. Finally, UBS Group upped their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus target price of $18.89.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.